PT-141 + Kisspeptin Libido Research Stack
Melanocortin (PT-141) + GnRH-axis (Kisspeptin) research stack targeting central sexual response and gonadal-axis research.
The PT-141 + Kisspeptin-10 research stack addresses sexual function from two mechanistically distinct angles: the central neural arousal axis and the upstream hypothalamic-pituitary-gonadal (HPG) axis. PT-141 (Bremelanotide) acts directly within the central nervous system at melanocortin-4 receptors (MC4R), initiating a neural arousal signal that is independent of vascular or hormonal status. Kisspeptin-10, by contrast, acts upstream at hypothalamic KNDy neurones to drive pulsatile GnRH release, which in turn governs LH-stimulated gonadal steroid output. The theoretical rationale for the combination is that central arousal signalling and HPG-axis pulsatility represent parallel, largely non-overlapping pathways — one governing the willingness to engage in sexual behaviour, the other governing the hormonal substrate that supports it. All content on this page describes preclinical and early-phase clinical research only.
Why pair PT-141 and Kisspeptin-10?
The prevailing models of sexual dysfunction distinguish between desire-phase deficits (insufficient central arousal signal) and hormonal-substrate deficits (insufficient circulating testosterone, LH pulsatility or gonadal steroidogenesis). PT-141 / Bremelanotide was developed specifically to bypass the hormonal substrate problem — its arousal signal is melanocortin-mediated, not androgen-dependent. The seminal preclinical work by James Pfaus at Concordia University demonstrated that MC4R agonism in rat models reliably produces appetitive and consummatory sexual behaviour regardless of circulating hormone levels [PMID:17672868].
Kisspeptin-10, the truncated biologically active fragment of the 54-amino-acid kisspeptin, addresses the complementary axis. The landmark 2003 publications by Stephanie Seminara at Massachusetts General Hospital and Nicolas de Roux in Paris independently identified loss-of-function mutations in GPR54 (the kisspeptin receptor) as a cause of idiopathic hypogonadotropic hypogonadism, establishing kisspeptin as the master upstream regulator of GnRH pulsatility [PMID:14573733; PMID:12944565]. The combination therefore operates on two non-redundant axes: Kisspeptin-10 primes the HPG axis toward endogenous hormone production, while PT-141 provides the rapid central arousal signal that does not depend on that hormonal output.
Mechanism of action — each peptide
PT-141 (Bremelanotide) — mechanism of action
PT-141, chemically known as Bremelanotide, is a cyclic heptapeptide agonist at melanocortin receptors MC3R and MC4R. Unlike the phosphodiesterase-5 inhibitors (sildenafil, tadalafil), which act peripherally on vascular smooth muscle, PT-141 initiates its primary signal within the central nervous system — specifically in the medial preoptic area (MPOA) of the hypothalamus, where MC4R density is highest in circuits governing motivated sexual behaviour.
The mechanism, established across a series of rat-model studies by James Pfaus and colleagues, involves MC4R-mediated activation of dopaminergic pathways in the nucleus accumbens and mesolimbic reward circuitry. This dopaminergic signal is thought to underlie the subjective increase in sexual desire — distinct from the peripheral erectile or lubrication response — observed in both animal models and early human trials. In the Phase II clinical programme, intranasal PT-141 produced erections in men with mild-to-moderate erectile dysfunction at rates significantly above placebo in a double-blind design [PMID:14963472].
Bremelanotide's FDA approval as Vyleesi (2019) for hypoactive sexual desire disorder (HSDD) in premenopausal women [PMID:31599840] rested on two Phase III RECONNECT trials demonstrating statistically significant improvements in desire domain scores and reductions in distress scores versus placebo. The approved clinical dose is 1.75 mg SC administered approximately 45 minutes before anticipated sexual activity. Research protocols typically explore the 1–2 mg range.
The plasma half-life of Bremelanotide is approximately 2.7 hours. The primary dose-limiting side effect is transient nausea, occurring in approximately 40% of subjects in clinical trials, followed by flushing and mild hypertension — the rationale for cardiovascular screening in any research context.
Kisspeptin-10 — mechanism of action
Kisspeptin-10 (KP-10) is the C-terminal decapeptide fragment of kisspeptin-54, encoded by the KISS1 gene, and represents the minimal biologically active unit capable of binding GPR54 (also designated KISS1R) with high affinity. GPR54 is a Gq-coupled receptor expressed densely on GnRH neurones in the arcuate nucleus (ARC) and anteroventral periventricular nucleus (AVPV) of the hypothalamus.
Waljit Dhillo and colleagues at Imperial College London conducted the first human pharmacology studies demonstrating that intravenous kisspeptin-54 produces a rapid, dose-dependent surge in LH within 30–60 minutes in healthy male volunteers [PMID:16174713], a finding subsequently extended to Kisspeptin-10 administered subcutaneously in research populations. The signalling cascade proceeds as follows: KP-10 binds GPR54 on GnRH-secreting neurones → Gq activation → IP3/DAG second messengers → GnRH pulse released into the portal circulation → pituitary LH and FSH secretion → gonadal testosterone or oestradiol synthesis.
Beyond its role in the HPG axis, the Dhillo laboratory and others have identified kisspeptin as a modulator of limbic and olfactory processing. A neuroimaging study by Comninos and colleagues (2017) demonstrated that exogenous kisspeptin administration in healthy men increased BOLD signal in the anterior cingulate cortex, hippocampus and amygdala in response to erotic visual stimuli, relative to placebo [PMID:28094765] — raising the possibility that kisspeptin exerts a direct central pro-sexual signal in addition to its HPG-axis endocrine role. This dual action provides a mechanistic basis for interest in kisspeptin as a complement to PT-141 rather than simply an additive hormonal support compound.
Kisspeptin-10 has a very short plasma half-life (estimated 3–4 minutes for IV delivery; somewhat longer for SC administration owing to absorption kinetics). Research protocols therefore use bolus or pulsatile dosing rather than continuous infusion.
Summarised studies on the combination
There are currently no published studies examining PT-141 and Kisspeptin-10 in direct co-administration in either animal models or human clinical trials. The combination represents a rational mechanistic hypothesis — dual-axis coverage of central arousal and HPG-axis pulsatility — rather than an empirically validated combination protocol. The following summarises the key studies for each component independently.
PT-141 / Bremelanotide: The Phase III RECONNECT trial programme (Kingsberg et al., 2019) [PMID:31599840] enrolled premenopausal women with HSDD in two randomised, double-blind, placebo-controlled trials. Across 1,247 subjects, subcutaneous Bremelanotide 1.75 mg demonstrated statistically significant improvement in the Female Sexual Function Index desire domain (primary endpoint) and a reduction in the Female Sexual Distress Scale — Desire/Arousal/Orgasm (FSD-DAO) score. The FDA approved Bremelanotide (Vyleesi) in June 2019, making it one of only two FDA-approved pharmacological treatments for HSDD in women. In the UK, Bremelanotide has not received MHRA authorisation and is not available as a licensed medicine.
Kisspeptin-10 in human research: Comninos et al. (2017) [PMID:28094765] administered intravenous kisspeptin-54 (a longer-acting prodrug form) to 29 healthy male volunteers in a double-blind crossover design, demonstrating both the predicted LH surge and, via fMRI, significant limbic-circuit activation during erotic stimulus processing. A follow-up study (Comninos and Dhillo, 2018) [PMID:28866693] extended this to show modulation of emotional processing more broadly. No Kisspeptin-10 study in combination with a melanocortin agonist has been registered or published as of the date of this article.
The absence of co-administration data means all synergy claims remain hypothetical and the protocol below is assembled from the individual compound literature only. Researchers designing combination protocols should note this limitation explicitly.
Full research protocol
The protocol below reflects the dosing ranges most commonly cited in the published literature for each compound individually, adapted for a four-week research window.
| Peptide | Dose | Frequency | Timing | Cycle length |
|---|---|---|---|---|
| PT-141 | 1–2 mg | As needed SC | 1–2 hours pre-event | 4 weeks max 2x/week |
| Kisspeptin-10 | 20–40 µg/kg | Single dose SC research bolus | Research-protocol dependent | Research bolus only |
Weekly research timeline
| Peptide | Wk 1 | Wk 2 | Wk 3 | Wk 4 |
|---|---|---|---|---|
| PT-141 | 1 mg 2x | 1.5 mg 2x | — | — |
| Kisspeptin-10 | 20 µg/kg | — | 20 µg/kg | — |
- Week 1: PT-141 introduced at 1 mg to establish tolerability before dose escalation. Kisspeptin-10 administered as a single research bolus on a designated study day; the bolus is not timed to PT-141 administration in published protocols.
- Week 2: PT-141 escalated to 1.5 mg if week 1 tolerance is confirmed. No Kisspeptin-10 bolus in this period — the HPG-axis response to week-1 bolus is monitored.
- Week 3: Second Kisspeptin-10 bolus administered. PT-141 continued at 1.5 mg twice weekly as needed.
- Week 4: PT-141 maintained; no further Kisspeptin-10 administration. Observation window for sustained LH-pulsatility changes.
The sparse Kisspeptin-10 timeline reflects the research literature: bolus KP-10 studies have used single or widely spaced doses rather than continuous weekly dosing, because the HPG-axis response to a single bolus is measurable for several days via serial LH sampling.
Reconstitution & storage notes
PT-141 (Bremelanotide): Available as a lyophilised powder; reconstitute in sterile water to a working concentration of 1–2 mg/mL. The reconstituted solution is stable at 2–8 °C for up to 21 days. Bremelanotide is also supplied in the approved clinical product as a pre-filled auto-injector in sterile solution (1.75 mg/0.4 mL); research-grade supply is typically the lyophilised form. Protect from repeated freeze-thaw; aliquot if storing beyond 21 days.
Kisspeptin-10: Supplied lyophilised. Reconstitute in sterile water or PBS at 0.5–1 mg/mL. Kisspeptin-10 is susceptible to peptide bond degradation at physiological pH over time; store lyophilised stock at −20 °C and use reconstituted solutions within 24–48 hours for optimal activity. Do not reconstitute in bacteriostatic water if the pH buffer is relevant to the research endpoint, as benzyl alcohol may interfere with some bioassay read-outs.
Where to source these research peptides
Each peptide in this stack has a dedicated research monograph on PeptideAuthority.co.uk and a research-grade SKU at PeptideBarn.co.uk. All compounds are sold strictly for in vitro research.
- PT-141 (Bremelanotide)Read full research Source research-grade PT-141 (Bremelanotide)
- Kisspeptin-10Read full research Source research-grade Kisspeptin-10
Related research
Researchers investigating the melanocortin-sexual response axis may also be interested in the Melanotan II + Bremelanotide Tanning Stack, which examines the overlapping MC1R/MC4R pharmacology of both non-selective melanocortin agonists in the context of pigmentation and libido research.
For broader neuroendocrine axis research involving growth-hormone-releasing peptides, the CJC-1295 + Ipamorelin + Tesamorelin GH Stack covers the pituitary-somatotroph axis and is frequently referenced alongside HPG-axis research given the overlapping regulatory pathways between GH and gonadal steroid secretion.
Frequently asked research questions
References
Peer-reviewed sources for the claims summarised above. Links open PubMed or the journal DOI.
- Pfaus JG, Giuliano F, Gelez H. Bremelanotide: an overview of preclinical CNS effects on female sexual function. Journal of Sexual Medicine. 2007;4(Suppl 4) :269-79 doi:10.1111/j.1743-6109.2007.00610.x · PMID: 17672868
- Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research. 2004;16(1) :51-9 doi:10.1038/sj.ijir.3901139 · PMID: 14963472
- Kingsberg SA, Clayton AH, Portman D, et al.. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology. 2019;134(5) :899-908 doi:10.1097/AOG.0000000000003500 · PMID: 31599840
- Dhillo WS, Chaudhri OB, Patterson M, et al.. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. Journal of Clinical Endocrinology and Metabolism. 2005;90(12) :6609-15 doi:10.1210/jc.2005-1468 · PMID: 16174713
- Comninos AN, Wall MB, Demetriou L, et al.. Kisspeptin modulates sexual and emotional brain processing in humans. Journal of Clinical Investigation. 2017;127(2) :709-719 doi:10.1172/JCI89519 · PMID: 28094765
- Seminara SB, Messager S, Chatzidaki EE, et al.. The GPR54 gene as a regulator of puberty. New England Journal of Medicine. 2003;349(17) :1614-27 doi:10.1056/NEJMoa035322 · PMID: 14573733
- de Roux N, Genin E, Carel JC, Matsuda F, Chaussain JL, Milgrom E. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proceedings of the National Academy of Sciences USA. 2003;100(19) :10972-6 doi:10.1073/pnas.1834399100 · PMID: 12944565
- Comninos AN, Dhillo WS. Emerging Roles of Kisspeptin in Sexual and Emotional Brain Processing. Neuroendocrinology. 2018;106(3) :195-202 doi:10.1159/000481296 · PMID: 28866693